Cystic fibrosis (CF) causes excess mucus and lung infections, impacting nearly 40,000 people in the US. Now, five biotech organisations are developing new treatments for the disease. Enterprise Therapeutics’ ETD001, a nebulised formulation, aims to increase hydration and clear mucus; Krystal Biotech offers the gene therapy KB407, targeting CFTR mutations; Recode Therapeutics is working on a similar therapy called RCT2100; Sionna Therapeutics’ SION-638 and SION-109 target different areas of protein mutation, and Vertex Pharmaceuticals continues developing trials for Trikafta and other CFTR modulators.
Boy, 17, among two more arrested on suspicion of murder after collision involving pedestrian
Two more people – including a 17-year-old boy – have been arrested on suspicion of murder after a man died following a collision in Barnsley.
